Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DC2DO5
|
|||
Drug Name |
PDC-1421
|
|||
Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Phase 2 | [1] | |
Company |
BioLite
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Norepinephrine transporter (NET) | Target Info | Inhibitor | [2] |
Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
WikiPathways | Monoamine Transport | |||
NRF2 pathway | ||||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02699086) A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD). U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of BioInvent. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.